Clinical Trial Update: Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating capivasertib plus docetaxel versus placebo plus docetaxel in metastatic castration-resistant prostate cancer; status is active, not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING